Recent Advances in Conventional and Molecular Prognostic Factors for Gastric Carcinoma

Surgical Oncology Clinics of North America

Volumn 17, Issue 3, 2008, Pages 467-483

  Nitti, Donato ^a   Mocellin, Simone ^a   Marchet, Alberto ^a   Pilati, Pierluigi ^a   Lise, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; PROTEIN P53; TELOMERASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR MARKER; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CELL ADHESION; CELL CYCLE; EARLY DIAGNOSIS; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; HUMAN; LIFE EXPECTANCY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PROGNOSIS; REVIEW; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; SURVIVAL RATE; SURVIVAL TIME;

APOPTOSIS; CELL CYCLE; DISEASE PROGRESSION; GENE EXPRESSION; GENES, P53; HUMANS; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 43449113860     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.02.010     Document Type: Review

References (115)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Hohenberger P., and Gretschel S. Gastric cancer. Lancet 362 (2003) 305-315
3. Dicken B.J., Bigam D.L., Cass C., et al. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 241 (2005) 27-39
4. Foukakis T., Lundell L., Gubanski M., et al. Advances in the treatment of patients with gastric adenocarcinoma. Acta Oncol 46 (2007) 277-285
5. Clark C.J., Thirlby R.C., Picozzi Jr. V., et al. Current problems in surgery: gastric cancer. Curr Probl Surg 43 (2006) 566-670
6. Hundahl S.A., Phillips J.L., and Menck H.R. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition. American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 88 (2000) 921-932
7. Inoue M., and Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J 81 (2005) 419-424
8. Greene F.L. TNM staging for malignancies of the digestive tract: 2003 changes and beyond. Semin Surg Oncol 21 (2003) 23-29
9. Yasui W., Oue N., Aung P.P., et al. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8 (2005) 86-94
10. Scartozzi M., Galizia E., Freddari F., et al. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 30 (2004) 451-459
11. Anderson C., Nijagal A., and Kim J. Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 10 (2006) 345-352
12. Sikora K. Personalized medicine for cancer: from molecular signature to therapeutic choice. Adv Cancer Res 96 (2007) 345-369
13. Trusheim M.R., Berndt E.R., and Douglas F.L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 6 (2007) 287-293
14. Takahashi I., Matsusaka T., Onohara T., et al. Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology 47 (2000) 1485-1488
15. Kikuchi S., Sato M., Katada N., et al. Surgical outcome of node-positive early gastric cancer with particular reference to nodal status. Anticancer Res 20 (2000) 3695-3700
16. Borch K., Jonsson B., Tarpila E., et al. Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg 87 (2000) 618-626
17. Msika S., Benhamiche A.M., Jouve J.L., et al. Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer 36 (2000) 390-396
18. Yokota T., Kunii Y., Teshima S., et al. Significant prognostic factors in patients with early gastric cancer. Int Surg 85 (2000) 286-290
19. Adachi Y., Shiraishi N., Suematsu T., et al. Most important lymph node information in gastric cancer: multivariate prognostic study. Ann Surg Oncol 7 (2000) 503-507
20. Crew K.D., and Neugut A.I. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 31 (2004) 450-464
21. Marchet A., Mocellin S., Ambrosi A., et al. The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients. Ann Surg 245 (2007) 543-552
22. Kim J.P., Lee J.H., Kim S.J., et al. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer 1 (1998) 125-133
23. Siewert J.R., Bottcher K., Stein H.J., et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228 (1998) 449-461
24. Liu C., Lu P., Lu Y., et al. Clinical implications of metastatic lymph node ratio in gastric cancer. BMC Cancer 7 (2007) 200
25. Kunisaki C., Makino H., Akiyama H., et al. Clinical significance of the metastatic lymph-node ratio in early gastric cancer. J Gastrointest Surg 12 (2008) 542-549
26. Celen O., Yildirim E., and Berberoglu U. Prognostic impact of positive lymph node ratio in gastric carcinoma. J Surg Oncol 96 (2007) 95-101
27. Cheong J.H., Hyung W.J., Shen J.G., et al. The N ratio predicts recurrence and poor prognosis in patients with node-positive early gastric cancer. Ann Surg Oncol 13 (2006) 377-385
28. Kunisaki C., Shimada H., Nomura M., et al. Clinical impact of metastatic lymph node ratio in advanced gastric cancer. Anticancer Res 25 (2005) 1369-1375
29. Rodriguez-Santiago J.M., Munoz E., Marti M., et al. Metastatic lymph node ratio as a prognostic factor in gastric cancer. Eur J Surg Oncol 31 (2005) 59-66
30. Nitti D., Marchet A., Olivieri M., et al. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol 10 (2003) 1077-1085
31. Takagane A., Terashima M., Abe K., et al. Evaluation of the ratio of lymph node metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer 2 (1999) 122-128
32. Inoue K., Nakane Y., Michiura T., et al. Histopathological grading does not affect survival after R0 surgery for gastric cancer. Eur J Surg Oncol 28 (2002) 633-636
33. Scartozzi M., Galizia E., Verdecchia L., et al. Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. Br J Cancer 95 (2006) 445-449
34. Hyung W.J., Lee J.H., Choi S.H., et al. Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol 9 (2002) 562-567
35. Kooby D.A., Suriawinata A., Klimstra D.S., et al. Biologic predictors of survival in node-negative gastric cancer. Ann Surg 237 (2003) 828-835 [discussion: 835-7]
36. Wanebo H.J., Kennedy B.J., Winchester D.P., et al. Role of splenectomy in gastric cancer surgery: adverse effect of elective splenectomy on longterm survival. J Am Coll Surg 185 (1997) 177-184
37. Nitti D., Marchet A., Mammano E., et al. Extended lymphadenectomy (D2) in patients with early gastric cancer. Eur J Surg Oncol 31 (2005) 875-881
38. Bonenkamp J.J., Hermans J., Sasako M., et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 340 (1999) 908-914
39. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79 (1999) 1522-1530
40. McCulloch P., Nita M.E., Kazi H., et al. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev (2004) CD001964
41. Cervantes A., Rodriguez Braun E., Perez Fidalgo A., et al. Molecular biology of gastric cancer. Clin Transl Oncol 9 (2007) 208-215
42. Hamilton J.P., and Meltzer S.J. A review of the genomics of gastric cancer. Clin Gastroenterol Hepatol 4 (2006) 416-425
43. Stock M., and Otto F. Gene deregulation in gastric cancer. Gene 360 (2005) 1-19
44. Kountouras J., Zavos C., and Chatzopoulos D. New concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology 52 (2005) 1305-1312
45. Ottini L., Falchetti M., Lupi R., et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 17 (2006) 97-102
46. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 (2004) 261-268
47. Ottini L., Falchetti M., Saieva C., et al. MRE11 expression is impaired in gastric cancer with microsatellite instability. Carcinogenesis 25 (2004) 2337-2343
48. Bacani J., Zwingerman R., Di Nicola N., et al. Tumor microsatellite instability in early onset gastric cancer. J Mol Diagn 7 (2005) 465-477
49. Gologan A., Krasinskas A., Hunt J., et al. Performance of the revised Bethesda guidelines for identification of colorectal carcinomas with a high level of microsatellite instability. Arch Pathol Lab Med 129 (2005) 1390-1397
50. Ottini L., Palli D., Falchetti M., et al. Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany. Cancer Res 57 (1997) 4523-4529
51. Simpson A.J., Caballero O.L., and Pena S.D. Microsatellite instability as a tool for the classification of gastric cancer. Trends Mol Med 7 (2001) 76-80
52. Schneider B.G., Bravo J.C., Roa J.C., et al. Microsatellite instability, prognosis and metastasis in gastric cancers from a low-risk population. Int J Cancer 89 (2000) 444-452
53. Choi S.W., Choi J.R., Chung Y.J., et al. Prognostic implications of microsatellite genotypes in gastric carcinoma. Int J Cancer 89 (2000) 378-383
54. Artunedo Pe P., Moreno Azcoita M., Alonso A., et al. Prognostic significance of high microsatellite instability in a Spanish series of gastric adenocarcinomas. Anticancer Res 20 (2000) 4009-4014
55. Azmy I.A., Balasubramanian S.P., Wilson A.G., et al. Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity. Breast Cancer Res 6 (2004) R395-R400
56. Wirtz H.C., Muller W., Noguchi T., et al. Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer. Clin Cancer Res 4 (1998) 1749-1754
57. Hayden J.D., Cawkwell L., Quirke P., et al. Prognostic significance of microsatellite instability in patients with gastric carcinoma. Eur J Cancer 33 (1997) 2342-2346
58. Beghelli S., de Manzoni G., Barbi S., et al. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery 139 (2006) 347-356
59. Noel A., Jost M., and Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 19 (2008) 52-60
60. de Mingo M., Moran A., Sanchez-Pernaute A., et al. Expression of MMP-9 and TIMP-1 as prognostic markers in gastric carcinoma. Hepatogastroenterology 54 (2007) 315-319
61. Liu X.P., Kawauchi S., Oga A., et al. Prognostic significance of matrix metalloproteinase-7 (MMP-7) expression at the invasive front in gastric carcinoma. Jpn J Cancer Res 93 (2002) 291-295
62. Lee K.H., Shin S.J., Kim K.O., et al. Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma. Oncol Rep 16 (2006) 823-830
63. Inoue T., Yashiro M., Nishimura S., et al. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med 4 (1999) 73-77
64. Caenazzo C., Onisto M., Sartor L., et al. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Clin Cancer Res 4 (1998) 2179-2186
65. Mimori K., Mori M., Shiraishi T., et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer 76 (1997) 531-536
66. Mrena J., Wiksten J.P., Nordling S., et al. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol 59 (2006) 618-623
67. Joo Y.E., Seo K.S., Kim H.S., et al. Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci 45 (2000) 114-121
68. Shah M.A., Ramanathan R.K., Ilson D.H., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24 (2006) 5201-5206
69. Lieto E., Ferraraccio F., Orditura M., et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15 (2008) 69-79
70. Kolev Y., Uetake H., Iida S., et al. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol 14 (2007) 2738-2747
71. Kondo K., Kaneko T., Baba M., et al. VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer. Biol Pharm Bull 30 (2007) 633-637
72. Nikiteas N.I., Tzanakis N., Theodoropoulos G., et al. Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer 10 (2007) 12-17
73. Juttner S., Wissmann C., Jons T., et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 24 (2006) 228-240
74. Shida A., Fujioka S., Ishibashi Y., et al. Prognostic significance of vascular endothelial growth factor D in gastric carcinoma. World J Surg 29 (2005) 1600-1607
75. Vidal O., Soriano-Izquierdo A., Pera M., et al. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg (2007) [epub ahead of print]
76. Roukos D.H., Liakakos T., Karatzas G., et al. Can VEGF-D and VEGFR-3 be used as biomarkers for therapeutic decisions in patients with gastric cancer?. Nat Clin Pract Oncol 3 (2006) 418-419
77. Wang T.B., Deng M.H., Qiu W.S., et al. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol 13 (2007) 1794-1797 [discussion: 179-8]
78. Bani-Hani K.E., Almasri N.M., Khader Y.S., et al. Combined evaluation of expressions of cyclin E and p53 proteins as prognostic factors for patients with gastric cancer. Clin Cancer Res 11 (2005) 1447-1453
79. Xiangming C., Natsugoe S., Takao S., et al. The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma. Cancer 89 (2000) 1214-1219
80. Feakins R.M., Nickols C.D., Bidd H., et al. Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol 34 (2003) 1276-1282
81. Fondevila C., Metges J.P., Fuster J., et al. p53 And VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90 (2004) 206-215
82. Pinto-de-Sousa J., Silva F., David L., et al. Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. Histopathology 44 (2004) 323-331
83. Okuyama T., Maehara Y., Kabashima A., et al. Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma. Oncology 63 (2002) 353-361
84. Feng C.W., Wang L.D., Jiao L.H., et al. Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer 2 (2002) 8
85. Carneiro F., Oliveira C., Suriano G., et al. Molecular pathology of familial gastric cancer. J Clin Pathol 61 (2008) 25-30
86. Machado J.C., Oliveira C., Carvalho R., et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 20 (2001) 1525-1528
87. Humar B., Graziano F., Cascinu S., et al. Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene 21 (2002) 8192-8195
88. Tanaka M., Kitajima Y., Sato S., et al. Combined evaluation of mucin antigen and E-cadherin expression may help select patients with gastric cancer suitable for minimally invasive therapy. Br J Surg 90 (2003) 95-101
89. Mingchao, Stockton P., Sun K., et al. Loss of E-cadherin expression in gastric intestinal metaplasia and later stage p53 altered expression in gastric carcinogenesis. Exp Toxicol Pathol 53 (2001) 237-246
90. Mocellin S., Provenzano M., Rossi C.R., et al. DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer. Ann Surg 241 (2005) 16-26
91. Mocellin S., Rossi C.R., Traldi P., et al. Molecular oncology in the post-genomic era: the challenge of proteomics. Trends Mol Med 10 (2004) 24-32
92. Hippo Y., Taniguchi H., Tsutsumi S., et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 62 (2002) 233-240
93. Hasegawa S., Furukawa Y., Li M., et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 62 (2002) 7012-7017
94. Marchet A., Mocellin S., Belluco C., et al. Gene expression profile of primary gastric cancer: towards the prediction of lymph node status. Ann Surg Oncol 14 (2007) 1058-1064
95. Inoue H., Matsuyama A., Mimori K., et al. Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res 8 (2002) 3475-3479
96. Yasui W., Oue N., Ito R., et al. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci 95 (2004) 385-392
97. Gyorffy B., and Lage H. A Web-based data warehouse on gene expression in human malignant melanoma. J Invest Dermatol 127 (2007) 394-399
98. Wolfrum F., Vogel I., Fandrich F., et al. Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. Langenbecks Arch Surg 390 (2005) 430-441
99. Cazzaniga G., Gaipa G., Rossi V., et al. Monitoring of minimal residual disease in leukemia, advantages and pitfalls. Ann Med 38 (2006) 512-521
100. Mocellin S., Keilholz U., Rossi C.R., et al. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med 12 (2006) 130-139
101. Mocellin S., Hoon D., Ambrosi A., et al. The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res 12 (2006) 4605-4613
102. Ishigami S., Sakamoto A., Uenosono Y., et al. Carcinoembryonic antigen messenger RNA expression in blood can predict relapse in gastric cancer. J Surg Res (2007) [epub ahead of print]
103. Uen Y.H., Lin S.R., Wu C.H., et al. Clinical significance of MUC1 and c-Met RT-PCR detection of circulating tumor cells in patients with gastric carcinoma. Clin Chim Acta 367 (2006) 55-61
104. Wu C.H., Lin S.R., Yu F.J., et al. Development of a high-throughput membrane-array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers. Int J Cancer 119 (2006) 373-379
105. Illert B., Fein M., Otto C., et al. Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosis. Scand J Gastroenterol 40 (2005) 843-849
106. Yeh K.H., Chen Y.C., Yeh S.H., et al. Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 (K19)-possible clinical significance in advanced gastric cancer. Anticancer Res 18 (1998) 1283-1286
107. Pituch-Noworolska A., Kolodziejczyk P., Kulig J., et al. Circulating tumour cells and survival of patients with gastric cancer. Anticancer Res 27 (2007) 635-640
108. Ikeguchi M., and Kaibara N. Detection of circulating cancer cells after a gastrectomy for gastric cancer. Surg Today 35 (2005) 436-441
109. Piva M.G., Navaglia F., Basso D., et al. CEA mRNA identification in peripheral blood is feasible for colorectal, but not for gastric or pancreatic cancer staging. Oncology 59 (2000) 323-328
110. Shin J.H., Chung J., Kim H.O., et al. Detection of cancer cells in peripheral blood of stomach cancer patients using RT-PCR amplification of tumour-specific mRNAs. Aliment Pharmacol Ther 16 Suppl 2 (2002) 137-144
111. Woodward W.A., Vinh-Hung V., Ueno N.T., et al. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol 24 (2006) 2910-2916
112. Rossi C.R., Mocellin S., Pasquali S., et al. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma. Ann Surg Oncol 15 (2008) 310-315
113. Malats N., Bustos A., Nascimento C.M., et al. p53 As a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6 (2005) 678-686
114. Zhu C.Q., Shih W., Ling C.H., et al. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59 (2006) 790-800
115. Mocellin S., Hoon D.S., Pilati P., et al. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol 25 (2007) 1588-1595